STOCK TITAN

IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

IRulya Therapeutics (Nasdaq: IRLA) granted restricted stock units representing 83,513 common shares as employment inducements for new employees.

The awards went to three new employees under the 2026 Inducement Plan. Vesting requires continued employment or service through each applicable vesting date. The first 25% vests on the last day of the calendar quarter containing the first anniversary of the Vesting Commencement Date; 6.25% vests at each quarter-end thereafter. The board approved the grants under Nasdaq Listing Rule 5635(c)(4), and the awards remain subject to the plan and applicable restricted stock unit agreements.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.83,513 common shares underlying employee restricted stock units create potential dilution as the awards vest.
Argus Nov 10 session 11 alerts
+14.34% close to close 1.9x rel. volume Open Argus
Details

News Market Reaction – IRLA

+8.4% Peak in 1 hr 52 min
$432.16M Mkt Cap at Peak Alert

On Nov 10, the first trading day after this news, IRLA closed 14.34% above the previous close. Argus tracked a peak move of +8.4% during that session. Our momentum scanner recorded 11 alerts for this stock that day. That session’s volume was 1.9x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Nov 10 session.

Key Figures

Restricted stock units granted: 83,513 shares Recipients: 3 employees Initial vesting: 25% +1 more
Restricted stock units granted
83,513 shares
Inducement grants to new employees
Recipients
3 employees
New employees receiving inducement grants
Initial vesting
25%
On the last day of the calendar quarter in which the first anniversary of the Vesting Commencement Date occurs
Subsequent vesting
6.25%
At the end of each calendar quarter thereafter

Key Terms

restricted stock units, vesting commencement date, nasdaq rule 5635(c)(4)
3 terms
restricted stock units financial
"granted restricted stock units representing a total of 83,513 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vesting commencement date financial
"the first anniversary of the Vesting Commencement Date occurs"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
nasdaq rule 5635(c)(4) regulatory
"approved by IRulya’s Board of Directors, as required by Nasdaq Rule 5635(c)(4)"
NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that on November 9, 2026, IRulya granted restricted stock units representing a total of 83,513 shares of common stock to three (3) new employees.

These inducement grants were granted pursuant to the IRulya Therapeutics Inc. 2026 Inducement Plan, subject to recipient’s continued employment or service through each applicable vesting date. Twenty-five percent (25%) of the shares subject to such award will vest on the last day of the calendar quarter in which the first anniversary of the Vesting Commencement Date occurs and 6.25% of the shares subject to such award vesting at the end of each calendar quarter thereafter. The inducement grants are subject to the terms and conditions of the applicable restricted stock unit agreements and the IRulya Therapeutics Inc. 2026 Inducement Plan.

The inducement grants were approved by IRulya’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).

About IRulya Therapeutics Inc.

IRulya Therapeutics Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a clinical study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b clinical study in PH-ILD is ongoing, and a Phase 2 clinical study in SAPH is anticipated to begin in the fourth quarter of 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.

Contact

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com 


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many inducement shares did IRulya Therapeutics grant to new employees?

IRulya granted restricted stock units representing 83,513 common shares to three new employees under its 2026 Inducement Plan. The board approved the awards as employment inducements under Nasdaq Listing Rule 5635(c)(4).

When do IRulya Therapeutics' employee inducement grants vest?

The first 25% vests on the last day of the calendar quarter containing the first anniversary of the Vesting Commencement Date, followed by 6.25% at each calendar quarter-end thereafter. Recipients must remain employed or in service through each applicable vesting date.

Keep reading